Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Hepta-refractory myeloma (CD38 mAbs, 2 IMiDs, 2 PIs, both BCMA- and GPRC5D-immunotherapies) shows median OS 12.8 months, PFS across salvage therapy lines 2.7-3.7 months; 1/3 patients show concurrent loss of BCMA & GPRC5D.”
Title: The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D
Authors: C. Riedhammer, M. Truger, H. Lee, LB Leypoldt, M. Meggendorfer, S. Hutter, H. Müller, J. Mersi, SK Kadel, T. Buchwald, R. Kosch, M. Helal, N. Afrin, A. Rosenwald, E. Gerhard-Hartmann, A. Brioli, J. Krönke, T. Haferlach, C. Haferlach, KC Weisel, P. Neri, H. Einsele, KM Kortüm, JM Waldschmidt, N. Bahlis, N. Weinhold, L. Rasche
You can read the Full Article in Leukemia.
You can find other articles featuring Robert Orlowski on OncoDaily.
